JCI-accredited partner hospitals

Obesity medicine · 2026

Weight loss in China,
medication to surgery, one pathway.

GLP-1 medications from $280/month, endoscopic procedures, and bariatric surgery from $9,500 — matched to your BMI and comorbidities at Class A metabolic centres. Multidisciplinary workup, bilingual reports, and a follow-up plan your home physician can run.

$280/mo

GLP-1 (semaglutide)

Wegovy 2.4mg vs ~$1,350 US list (~80% off)

NMPA-listed pricing 2024

$420/mo

GLP-1 (tirzepatide)

10–15mg titration dose vs ~$1,080 US

NMPA-listed pricing 2024

$9,500+

Sleeve gastrectomy

All-in vs $15,000–25,000 US private

Partner-hospital quotes 2024

25–35%

Total weight loss (surgery)

At 1–2 years, durable for most patients

IFSO / bariatric literature

Class A

Metabolic centres

CSMBS / IFSO-recognised bariatric programs

NHC ratings

MDT

Endocrine + nutrition + psych

Multidisciplinary workup is standard

IFSO guidelines

Tiers & pricing

One ladder, from medication to surgery.

First-line

Medical weight management

Endocrinology consult, metabolic labs, structured nutrition + resistance-training prescription, body-composition baseline. The foundation under every other tier.

$650–1,250 first visit

BMI 27–35

GLP-1 medication

Semaglutide (~14–17% loss) or tirzepatide (~21% loss). NMPA-approved, hospital-pharmacy dispensed, bilingual prescription + customs letter.

$280–420 / month

BMI 27–35

Endoscopic options

Intragastric balloon or ESG (endoscopic sleeve gastroplasty) — non-surgical, for patients not meeting or not wanting surgical criteria.

$5,500–9,500

BMI ≥ 35

Sleeve gastrectomy

Laparoscopic vertical sleeve — the most common bariatric operation. ~25–30% total weight loss at 1 year. Lower reoperation than bypass.

$9,500–13,500

Metabolic

Gastric bypass / SADI-S

RYGB and SADI-S for severe type 2 diabetes and higher BMI. Strongest diabetes-remission and long-term durability profile.

$12,000–19,000

Complex

Revision surgery

Sleeve-to-bypass or sleeve-to-SADI-S revision for inadequate weight loss, weight regain, or refractory reflux.

$14,000–22,000

Top hospitals

Six centres
open to international patients.

Shanghai

Shanghai Sixth People's Hospital 上海第六人民医院

National reference for diabetes and obesity surgery · MDT metabolic program

Beijing

Peking University People's Hospital 北京大学人民医院

Class A teaching · high-volume sleeve and bypass · CSMBS-recognised

Shanghai

Zhongshan Hospital, Fudan University 中山医院

Class A · academic centre · revision surgery experience

Guangzhou

First Affiliated Hospital, Sun Yat-sen University 中山一院

Class A · regional reference for metabolic and bariatric surgery

Beijing

Beijing Friendship Hospital 北京友谊医院

Class A · strong metabolic surgery program · MDT obesity clinic

Multi-city

United Family Hospitals 和睦家

JCI · expat-focused · endocrinology-led GLP-1 and medical weight management

Cost comparison

China vs US vs UK,
real weight-loss pricing.

China
United States
United Kingdom
Semaglutide (Wegovy) / month
~$280
~$1,350
£150–£250
Tirzepatide / month
~$420
~$1,080
£150–£220
Intragastric balloon / ESG
$5,500–$9,500
$8,000–$16,000
£4,000–£9,000
Sleeve gastrectomy
$9,500–$13,500
$15,000–$25,000
£9,500–£13,500
Gastric bypass (RYGB)
$12,000–$16,500
$22,000–$32,000
£11,500–£16,000

Sources: NMPA-listed pharmacy pricing 2024, ASMBS / Healthcare Bluebook 2024, NHS / Bupa UK 2024, partner-hospital itemized quotes 2024–2025. GLP-1 pricing is per-month medication only; surgical pricing is all-in and excludes airfare, accommodation and complications. Educational only — not medical advice.

FAQ

Weight loss in China — answered.

Medication or surgery — which is right for me?
It depends on your BMI and comorbidities. For BMI 27–35 without significant comorbidity, GLP-1 medication (semaglutide or tirzepatide) is typically first-line and achieves 14–21% weight loss while taken. For BMI ≥ 35 with comorbidities, or BMI ≥ 40, bariatric surgery has the strongest long-term durability evidence (25–35% total weight loss sustained at 5+ years) — though many patients trial GLP-1 first. Endoscopic options (balloon, ESG) sit in between for BMI 27–35 who want a procedure without surgery. We match a recommendation to your profile after an endocrinology and, where relevant, surgical assessment.
How much does weight loss treatment cost in China?
GLP-1 medication runs ~$280/month for semaglutide (Wegovy) or ~$420/month for tirzepatide — roughly 60–80% below US list prices — plus a $650–1,250 first-visit workup package. Endoscopic options (balloon / ESG) are $5,500–9,500. Bariatric surgery is all-in $9,500–13,500 for sleeve, $12,000–16,500 for gastric bypass, and $14,500–19,000 for SADI-S. Surgical quotes include surgeon, anaesthesia, ward stay and pre-op workup; they exclude airfare, accommodation and complications cover.
Are semaglutide and tirzepatide legally available in China?
Yes. Semaglutide (Ozempic) was NMPA-approved for type 2 diabetes in 2021 and Wegovy 2.4mg for chronic weight management in mid-2024. Tirzepatide was approved for T2D in mid-2024 and for weight management in late-2024 / early-2025. Both are dispensed by Class A hospital pharmacies with a bilingual prescription and a physician's letter for customs. A domestic GLP-1 (beinaglutide) is also NMPA-indicated for obesity. See our GLP-1 guide for the full pricing and supply picture.
How much weight will I actually lose?
Honest ranges from registry and phase-3 data: semaglutide 2.4mg ~14–17% of body weight at 68 weeks; tirzepatide 15mg ~21% at 72 weeks; sleeve gastrectomy ~25–30% total weight loss at 1 year; gastric bypass / SADI-S ~30–35%. Individual response varies and most loss occurs in months 3–12. Whether that loss preserves lean mass depends on nutrition and resistance training — we bundle a structured prescription and re-check body composition at 6 and 12 months.
What happens if I stop GLP-1 medication?
Most patients regain a substantial share of the weight after stopping GLP-1s — these are treatments for a chronic condition, not a course you finish. That is a key reason patients with higher BMI and comorbidities often move to bariatric surgery, which produces more durable loss. If you take the medication route, plan for long-term maintenance and confirm a home-country prescriber before you rely on it. We provide a bilingual medication and follow-up plan for that handover.
Who is eligible for bariatric surgery, and what does follow-up require?
Eligibility follows IFSO criteria: broadly BMI ≥ 32.5 with metabolic disease (T2D, severe sleep apnoea, fatty liver) or BMI ≥ 37.5 without comorbidity, age 18–65 (some centres to 70 with screening), able to commit to lifelong follow-up and free of untreated psychiatric illness or active substance abuse. Surgery requires lifelong supplementation (multivitamin, B12, vitamin D, calcium, iron) and scheduled labs. Before travelling, you must confirm a home-country physician or dietitian to manage long-term follow-up; we supply a bilingual operative note, nutrition plan and lab schedule.

Send your BMI and labs
for a written pathway.

Share your BMI, comorbidities and recent labs. We return a written recommendation from a partner endocrinologist or bariatric surgeon — which of the medication, endoscopic and surgical paths fit your case, with indicative cost and a follow-up plan for your home team.

This page is for general information only and does not constitute medical advice. Obesity is a chronic condition; no treatment guarantees a specific weight loss, and medication weight loss is typically regained if treatment stops. GLP-1 medications and bariatric surgery both carry risks reviewed by the treating physician. All clinical decisions are made by the treating physician at the partner hospital after assessment.